Health Products

Teva-Mirtazapine

· Published by Health Canada · Official notice

Details

Alert type: Recall
Category: Drugs
Department: Health Canada
Hazard classification: Type II
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberCommon nameCompaniesDosage formDIN, NPN, DIN-HIMStrength
M31006 (15 mg) M31007 (15 mg) M31008 (15 mg) M31009 (15 mg) M33006 (45 mg) M33007 (45 mg)Teva-Mirtazapine
Recalling Firm
Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9
Marketing Authorization Holder
Teva Pharmaceutical 64 Hashikma Street, Industrial Zone, Kfar-Saba, Israel, 44102
TabletTeva-Mirtazapine OD 15 mg comprimés, DIN # 02279894 Teva Mirtazapine OD 45 mg comprimés, DIN # 0227991615 mg / tablet, 45 mg / tablet

Reason

Upon testing the 36 month stability time points for Mirtazapine lot M31004 15 mg and lot M33004 45 mg OD Tablets (30's unit dose packaging), out of specification (OOS) and out of trend (OOT) results were identified respectively. As per specification, the limit for any individual impurity is NMT 0.2%. The results for the tested batches indicated an impurity at RRT 0.8 to be 0.3% and 0.2% respectively. Six lots within expiry will be recalled from the Canadian market.

Depth of distribution

Product was distributed to wholesalers/retailers in NF, NS, QC, ON, MB, AB, SK and BC.
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime